Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Filter articles using the following links
Financial press releases
Events & presentations
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
25 Apr 2020 - 01 May 2020
2020 AAN Annual Meeting, Toronto, Canada – canceled due to COVID-19
21 April 2020
GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update
15 April 2020
GenSight Biologics on Track to Submit LUMEVOQ® for European Approval in September 2020 Following Pre-Submission Meeting with EMA
14 April 2020
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa
19 Apr 2020 - 21 Apr 2020
H.C. Wainwright Global Life Sciences Conference, London, UK – cancelled
08 April 2020
Annual General Meeting on April 29, 2020 Procedures for obtaining preparatory documents for the General Meeting
08 April 2020
GenSight Biologics Announces the Filing of its 2019 Universal Registration Document
06 April 2020
GenSight Biologics Provides Update on Operations in the Context of COVID-19
12 March 2020
GenSight Biologics Reports Full Year 2019 Financial Results and provides an Outlook on 2020
03 March 2020
GenSight Biologics announces presentation of bilateral visual recovery from GS010 (LUMEVOQ™) Phase III trials at the 46th annual meeting of NANOS
View previous 9 articles
1
…
15
16
17
18
19
20
21
22
23
24
25
…
40
View next 9 articles
Go back to the page of the page